Edition:
United Kingdom

Sino Biopharmaceutical Ltd (1177.HK)

1177.HK on Hong Kong Stock

9.36HKD
16 Aug 2018
Change (% chg)

HK$-0.16 (-1.68%)
Prev Close
HK$9.52
Open
HK$9.26
Day's High
HK$9.75
Day's Low
HK$9.20
Volume
74,687,417
Avg. Vol
46,823,630
52-wk High
HK$13.93
52-wk Low
HK$4.33

Latest Key Developments (Source: Significant Developments)

Sino Biopharmaceutical Announces Passing Of EU GMP Certification For Tenofovir Production Line
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::ANNOUNCES PASSING OF EU GMP CERTIFICATION FOR TENOFOVIR PRODUCTION LINE.  Full Article

Sino Biopharmaceutical Says Obtained Drug Registration Approval For Bortezomib
Friday, 20 Jul 2018 

July 20 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::BORTEZOMIB FOR INJECTION OBTAINED APPROVAL FOR DRUG REGISTRATION BY NATIONAL DRUG ADMINISTRATION -PEOPLE'S REPUBLIC OF CHINA.  Full Article

Sino Biopharmaceutical Says Injection Obtained Drug Registration Approval By National Drug Administration
Wednesday, 27 Jun 2018 

June 27 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::DOCETAXEL INJECTION HAS OBTAINED APPROVAL FOR DRUG REGISTRATION BY NATIONAL DRUG ADMINISTRATION OF PEOPLE'S REPUBLIC OF CHINA.  Full Article

Sino Biopharmaceutical Says Trustee Purchased 5.1 Mln Shares Pursuant To Restricted Share Award Scheme
Friday, 1 Jun 2018 

June 1 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::FROM 23 MAY TO 1 JUNE , TRUSTEE PURCHASED 5.1 MILLION SHARES FROM MARKET TO HOLD ON TRUST FOR PARTICIPANTS FOR HK$97.4 MILLION.  Full Article

Sino Biopharmaceutical Posts Qtrly Net Profit Of RMB771.1 Mln
Friday, 18 May 2018 

May 18 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::QTRLY REVENUE WAS ABOUT RMB4,652.61 MILLION, UP 20.4%.QTRLY NET PROFIT RMB771.1 MILLION VERSUS RMB 579 MILLION.DECLARED PAYMENT OF A FIRST QUARTERLY DIVIDEND OF HK2 CENTS PER SHARE.  Full Article

Sino Biopharmaceutical Says Compound Sodium Acetate Ringer's Injection Gets Drug Registration Approvals
Wednesday, 2 May 2018 

May 2 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::COMPOUND SODIUM ACETATE RINGER'S INJECTION OBTAINS TWO APPROVALS FOR DRUG REGISTRATION BY CHINA FOOD AND DRUG ADMINISTRATION.  Full Article

Sino Biopharmaceutical Announces Proposed Bonus Issue Of Shares
Tuesday, 17 Apr 2018 

April 17 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::RECOMMENDS A BONUS ISSUE OF SHARES ON BASIS OF ONE BONUS SHARE FOR EVERY TWO EXISTING SHARES HELD BY QUALIFYING SHAREHOLDERS.EXPECTED THAT A TOTAL OF 4.21 BILLION BONUS SHARES WOULD BE ALLOTTED AND ISSUED.  Full Article

Sino Biopharmaceutical Co Announces Acquisition of Sino Biopharm Beijing​ & Super Demand
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::CO TO ACQUIRE SINO BIOPHARM BEIJING​,WHICH OWNS 33.6% OF BEIJING TIDE, BY ISSUING 723.3 MILLION SHARES AT HK$12.73 PER ISSUE SHARE.‍FRANCE INVESTMENT (CHINA 1) GROUP TO SELL 52 PERCENT STAKE IN SUPER DEMAND FOR HK$3.69 BILLION TO CO ​.  Full Article

Sino Biopharmaceutical Product Granted Drug Registration Approval By State FDA Of China​
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::"TENOFOVIR DISOPROXIL FUMARATE TABLET" GRANTED DRUG REGISTRATION APPROVAL BY STATE FOOD AND DRUG ADMINISTRATION OF CHINA​.‍TENOFOVIR DISOPROXIL FUMARATE GRANTED APPROVAL FOR TREATMENT OF CHRONIC HEPATITIS B​.  Full Article

Sino Biopharmaceutical posts 9-month ‍net profit attributable of RMB1.80​ bln
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK> ::9-month ‍revenue RMB11,446.73 million, up 9.5​ percent.‍Declared payment of a third quarterly dividend of HK2 cents per share for three months ended 30 Sept​.9-month net profit attributable to owners RMB1.80​ billion versus RMB1.30 billion.  Full Article

BRIEF-Sino Biopharmaceutical Gets Approval From China FDA To Register Unit's Drug

* DRUG DEVELOPED BY UNIT GETS APPROVAL FOR DRUG REGISTRATION BY CHINA FOOD AND DRUG ADMINISTRATION Source text for Eikon: Further company coverage: